Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase EARLY_PHASE1 2Phase 1/2 2Phase 3 1

Status

Completed 18Terminated 8Active not recruiting 6Withdrawn 3Unknown 3Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 1Glioblastoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × niraparib × Clear all
NCT06161493 2024-10-15

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

University of Pittsburgh

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT05666349 2024-03-26

RiNG

University College, London

Phase 1 Withdrawn
CNS

Glioblastoma

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Wake Forest University Health Sciences

Phase 1 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡